July 24, 2010 -- China life science IPOs raised $5.4 billion in the last 12 months, led by the $1.3 billion IPO of Sinopharm Group; China’s central government spent $11.8 billion on healthcare reform in the first half of 2010; CCBI Healthcare Fund made an investment in Shanghai Kindly Enterprise Development Group; Lijun International Pharmaceutical set up a Joint Venture with Tonghua Dongbao Pharma in Jilin Province; BioHorizons has asked the SFDA for approval of its dental implant products; BMP Sunstone rose more than 10% on Monday on rumors it would be acquired; Lee’s Pharma will be the exclusive China distributor for Remodulin, a United Therapeutics product; Beike Biotechnology opened a rehabilitation center in Romania; Novartis reported the SFDA has approved China use of Rasilez®, a treatment for high blood pressure; and Bayer Schering AG and The People’s Liberation Army General Hospital (301 Hospital) of Beijing have begun a research collaboration to study women’s health. More details....
Stock Symbols: (HKEX: 0939) (HKEX: 02005) (SHEX: 600867) (NSDQ: BJGP) (GEM: 8221) (NSDQ: UTHR) (NYSE: NVS)
Richard Daverman, Editor ChinaBio(r) Today 858.663.1184 rdaverman@chinabiollc.com
